Nasdaq approved Canary Capital’s Staked INJ ETF listing on November 4, 2026, giving Injective’s INJ token a route into the regulated US securities market with potential staking rewards. The Injective ETF approval marks an institutional milestone, but it is not the start of trading. Separately, INJ recovered to around $7.64 , above a closely followed breakout level.
Key takeaways
Canary Capital’s Staked INJ ETF received Nasdaq listing approval.
The fund combines INJ exposure with potential staking rewards.
INJ gained approximately 9% over 24 hours to around $7.64.
Listing approval and the ETF’s trading launch are separate steps.
Injective’s INJ ETF approval opens a regulated investment route
With Canary Capital’s Staked INJ ETF , INJ now has its first regulated exchange-traded product available in the United States. Its structure brings together traditional investment access and crypto staking exposure, offering an alternative to holding the token directly.
The fund is designed to give investors exposure to INJ and potential staking rewards without requiring them to manage tokens or operate staking infrastructure. Exchange-traded access also makes the asset more accessible to investors who prefer traditional brokerage accounts.
According to Eagle.inj, the approval reflects years of development, innovation and ecosystem growth. For Injective, the milestone opens an institutional demand channel through a regulated securities-market product.
Listing approval does not mean immediate trading. The fund’s launch and subsequent investor participation remain separate developments, and approval alone does not establish the level of demand.
INJ clears $7.30 as technical signals remain mixed
INJ’s reported recovery to around $7.64 put it above the $7.30 breakout level identified by crypto analyst Trader Symba. Market data showed an approximately 9% gain over 24 hours .
Trader Symba said INJ had broken out of a wedge formation and successfully retested the breakout area. The analyst identified $7.30 as resistance that buyers had overcome, with an initial target of $7.55 and a potential extension toward $8.00–$8.20 .
The reported $7.64 price had already exceeded that first target. The higher range remained a conditional projection tied to continued buying and maintenance of the breakout structure.
The moving averages gave a less decisive picture. INJ’s price sat above the seven-day moving average yet remained under the 20-day moving average, which was close to $7.92 . Its Relative Strength Index was around 50, indicating relatively neutral momentum rather than clear confirmation of a stronger uptrend.
ETF launch and $7.92 mark the next tests
The Staked INJ ETF’s eventual launch and initial fund flows will provide a clearer measure of institutional demand. On the price chart, a sustained move above $7.92 would strengthen the recovery and bring Trader Symba’s higher target range into focus.
The Injective INJ ETF approval and the token’s breakout represent different developments: one establishes exchange-listing access, while the other reflects the reported price recovery. Actual fund participation will offer evidence of investor interest beyond the approval itself.
For the technical setup, sustained buying remains the condition attached to the higher price targets. Following the breakout, $7.30 serves as the support reference, while the 20-day moving average sits near $7.92.
Article produced with the assistance of artificial intelligence and reviewed by the editorial team.
